SCHEMBL3881763

SCHEMBL3881763

O=C(O)CCc1ccc(OC2CCCC2)c(-c2ccc3sccc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 10/20 0.47
S1PR1 P21453 2/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
FFAR1 O14842 2/20 0.40
CA12 O43570 1/20 0.39
ENPP1 P22413 1/20 0.39
SIGMAR1 Q99720 2/20 0.38
BCL9 O00512 2/20 0.37
CTNNB1 P35222 2/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884101 0.99 FFAR4 (0.46) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3687420 0.86 THRA (0.46) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3881912 0.84 S1PR1 (0.49) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3679192 0.83 FFAR4 (0.58) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3883711 0.82 FFAR4 (0.57) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3678537 0.81 FFAR4 (0.50) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL7733967 0.81 FFAR4 (0.50) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3883951 0.80 S1PR1 (0.46) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3885129 0.80 FFAR4 (0.48) FFAR4S1PR1THRATHRBFFAR1
SCHEMBL3882882 0.80 FFAR4 (0.49) FFAR4S1PR1THRATHRBFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885S1PR1 77/4885THRA 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.